Cargando…
Production of biologically active recombinant buffalo leukemia inhibitory factor (BuLIF) in Escherichia Coli
BACKGROUND: Leukemia inhibitory factor (LIF) is a multifunctional cytokine which plays multiple roles in different biological processes such as implantation, bone remodeling, and hematopoiesis. The buESCs are difficult to culture due to lack of proper understanding of the culture conditions. LIF is...
Autores principales: | , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer Berlin Heidelberg
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8927517/ https://www.ncbi.nlm.nih.gov/pubmed/35294648 http://dx.doi.org/10.1186/s43141-022-00328-1 |
_version_ | 1784670460416360448 |
---|---|
author | Jamwal, Shradha Ansari, Shama Malakar, Dhruba Kaushik, Jai Kumar Kumar, Sudarshan Mohanty, Ashok Kumar |
author_facet | Jamwal, Shradha Ansari, Shama Malakar, Dhruba Kaushik, Jai Kumar Kumar, Sudarshan Mohanty, Ashok Kumar |
author_sort | Jamwal, Shradha |
collection | PubMed |
description | BACKGROUND: Leukemia inhibitory factor (LIF) is a multifunctional cytokine which plays multiple roles in different biological processes such as implantation, bone remodeling, and hematopoiesis. The buESCs are difficult to culture due to lack of proper understanding of the culture conditions. LIF is one of the important factors which maintain the pluripotency in embryonic stem cells and commercial LIF from murine and human origin is used in the establishment of buffalo embryonic stem cells (buESCs). The LIF from a foreign origin is not able to maintain pluripotency and proliferation in buESCs for a long term which is contributed by difference in the binding sites on LIF; therefore, culture medium supplemented with buffalo-specific LIF may enhance the efficiency of buESCs by improving the environment of culture conditions. The high cost of LIF is another major drawback which restricts buESCs research, thus limits the scope of buffalo stem cell use. Various methods have been developed to produce human and murine LIF in prokaryotic system. However, Buffalo leukemia inhibitory factor (BuLIF) has not been yet produced in prokaryotic system. Here, we describe a simple strategy for the expression and purification of biologically active BuLIF in Escherichia coli (E. coli). RESULTS: The BuLIF cDNA from buffalo (Bubalus bubalis) was cloned into pET22b(+) and expressed in E. coli Lemo-21(DE3). The expression of BuLIF was directed into periplasmic space of E. coli which resulted in the formation of soluble recombinant protein. One step immobilized metal affinity chromatography (IMAC chromatography) was performed for purification of BuLIF with ≥ 95% of homogeneity. The recombinant protein was confirmed by western blot and identified by mass spectroscopy. The biological activity of recombinant BuLIF was determined on murine myeloid leukemic cells (M1 cells) by MTT proliferation assay. The addition of BuLIF increased the reduction of MTT by stimulated M1 cells in a dose-dependent manner. The BuLIF induced the formation of macrophage like structures from M1 cells where they engulfed fluorescent latex beads. The recombinant BuLIF successfully maintained pluripotency in buffalo embryonic stem cells (buESCs) and were positive for stem cells markers such as Oct-4, Sox-2, Nanog, and alkaline phosphatase activity. CONCLUSIONS: The present study demonstrated a simple method for the production of bioactive BuLIF in E. coli through single step purification. BuLIF effectively maintained buffalo embryonic stem cells pluripotency. Thus, this purified BuLIF can be used in stem cell study, biomedical, and agricultural research. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s43141-022-00328-1. |
format | Online Article Text |
id | pubmed-8927517 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | Springer Berlin Heidelberg |
record_format | MEDLINE/PubMed |
spelling | pubmed-89275172022-04-01 Production of biologically active recombinant buffalo leukemia inhibitory factor (BuLIF) in Escherichia Coli Jamwal, Shradha Ansari, Shama Malakar, Dhruba Kaushik, Jai Kumar Kumar, Sudarshan Mohanty, Ashok Kumar J Genet Eng Biotechnol Research BACKGROUND: Leukemia inhibitory factor (LIF) is a multifunctional cytokine which plays multiple roles in different biological processes such as implantation, bone remodeling, and hematopoiesis. The buESCs are difficult to culture due to lack of proper understanding of the culture conditions. LIF is one of the important factors which maintain the pluripotency in embryonic stem cells and commercial LIF from murine and human origin is used in the establishment of buffalo embryonic stem cells (buESCs). The LIF from a foreign origin is not able to maintain pluripotency and proliferation in buESCs for a long term which is contributed by difference in the binding sites on LIF; therefore, culture medium supplemented with buffalo-specific LIF may enhance the efficiency of buESCs by improving the environment of culture conditions. The high cost of LIF is another major drawback which restricts buESCs research, thus limits the scope of buffalo stem cell use. Various methods have been developed to produce human and murine LIF in prokaryotic system. However, Buffalo leukemia inhibitory factor (BuLIF) has not been yet produced in prokaryotic system. Here, we describe a simple strategy for the expression and purification of biologically active BuLIF in Escherichia coli (E. coli). RESULTS: The BuLIF cDNA from buffalo (Bubalus bubalis) was cloned into pET22b(+) and expressed in E. coli Lemo-21(DE3). The expression of BuLIF was directed into periplasmic space of E. coli which resulted in the formation of soluble recombinant protein. One step immobilized metal affinity chromatography (IMAC chromatography) was performed for purification of BuLIF with ≥ 95% of homogeneity. The recombinant protein was confirmed by western blot and identified by mass spectroscopy. The biological activity of recombinant BuLIF was determined on murine myeloid leukemic cells (M1 cells) by MTT proliferation assay. The addition of BuLIF increased the reduction of MTT by stimulated M1 cells in a dose-dependent manner. The BuLIF induced the formation of macrophage like structures from M1 cells where they engulfed fluorescent latex beads. The recombinant BuLIF successfully maintained pluripotency in buffalo embryonic stem cells (buESCs) and were positive for stem cells markers such as Oct-4, Sox-2, Nanog, and alkaline phosphatase activity. CONCLUSIONS: The present study demonstrated a simple method for the production of bioactive BuLIF in E. coli through single step purification. BuLIF effectively maintained buffalo embryonic stem cells pluripotency. Thus, this purified BuLIF can be used in stem cell study, biomedical, and agricultural research. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s43141-022-00328-1. Springer Berlin Heidelberg 2022-03-16 /pmc/articles/PMC8927517/ /pubmed/35294648 http://dx.doi.org/10.1186/s43141-022-00328-1 Text en © The Author(s) 2022 https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . |
spellingShingle | Research Jamwal, Shradha Ansari, Shama Malakar, Dhruba Kaushik, Jai Kumar Kumar, Sudarshan Mohanty, Ashok Kumar Production of biologically active recombinant buffalo leukemia inhibitory factor (BuLIF) in Escherichia Coli |
title | Production of biologically active recombinant buffalo leukemia inhibitory factor (BuLIF) in Escherichia Coli |
title_full | Production of biologically active recombinant buffalo leukemia inhibitory factor (BuLIF) in Escherichia Coli |
title_fullStr | Production of biologically active recombinant buffalo leukemia inhibitory factor (BuLIF) in Escherichia Coli |
title_full_unstemmed | Production of biologically active recombinant buffalo leukemia inhibitory factor (BuLIF) in Escherichia Coli |
title_short | Production of biologically active recombinant buffalo leukemia inhibitory factor (BuLIF) in Escherichia Coli |
title_sort | production of biologically active recombinant buffalo leukemia inhibitory factor (bulif) in escherichia coli |
topic | Research |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8927517/ https://www.ncbi.nlm.nih.gov/pubmed/35294648 http://dx.doi.org/10.1186/s43141-022-00328-1 |
work_keys_str_mv | AT jamwalshradha productionofbiologicallyactiverecombinantbuffaloleukemiainhibitoryfactorbulifinescherichiacoli AT ansarishama productionofbiologicallyactiverecombinantbuffaloleukemiainhibitoryfactorbulifinescherichiacoli AT malakardhruba productionofbiologicallyactiverecombinantbuffaloleukemiainhibitoryfactorbulifinescherichiacoli AT kaushikjaikumar productionofbiologicallyactiverecombinantbuffaloleukemiainhibitoryfactorbulifinescherichiacoli AT kumarsudarshan productionofbiologicallyactiverecombinantbuffaloleukemiainhibitoryfactorbulifinescherichiacoli AT mohantyashokkumar productionofbiologicallyactiverecombinantbuffaloleukemiainhibitoryfactorbulifinescherichiacoli |